First granted ICOone® patent in India
Iconovo AB (publ) has been granted its first patent in India on the inhalation platform ICOone®. Iconovo has previously granted ICOone® patents in Europe (EPO) and have several patents pending in USA, India, China and Japan.
ICOone® is Iconovo’s platform for simple and cost-efficient delivery of vaccines and biomolecules to the lung. Since ICOone® delivers a dry powder, there is no need for expensive and complicated cold storage. Inhaling the drug eliminates the use of disposable syringes and no hazardous waste with blood contaminated syringes is generated.
A good example of ICOone® use is the cooperation with Monash University. In this project Oxytocin is administered to women during birth to prevent heavy bleeding, Postpartum Hemorrhage (PPH). Oxytocin is today typically delivered as an injection and requires cold storage, which can be very challenging in regions with less developed infrastructure. PPH is globally the most common cause of maternal mortality with over 60 000 fatalities annually. India represents a significant part of all PPH cases.
”A patent in India is extremely important for us since it is a large potential market for which ICOone® is particularly well suited. A cheap, simple and safe way to supply vaccines to a large population is of great interest to many of our potential customers, not the least in India”, says Dr. Orest Lastow, CTO and founder at Iconovo.
ICOone® is a unique, patented dry powder inhaler for single use. The smart design generates an ultra-low manufacturing cost combined with simple and discreet use. It is particularly suitable for short-term treatment and as-needed use as it provides an unsurpassed low treatment cost and price point for treatments with a low number of doses. The simple design also enables patients and caregivers to learn how to handle the inhalers with minimal training. ICOone® can deliver large inhalation doses that are well protected against moisture, an important factor for many biomolecules.